<DOC>
	<DOCNO>NCT00387374</DOCNO>
	<brief_summary>This phase II trial study side effect well give radiation therapy together bevacizumab , paclitaxel , carboplatin work treat patient unresectable stage IIIB stage IV non-small cell lung cancer high risk hemoptysis cause bevacizumab . Radiation therapy use high-energy x-ray kill tumor cell . It may also prevent hemoptysis cause bevacizumab . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth non-small cell lung cancer block blood flow tumor . Drugs use chemotherapy , paclitaxel carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving radiation therapy together bevacizumab chemotherapy may kill tumor cell</brief_summary>
	<brief_title>Radiation Therapy , Bevacizumab , Paclitaxel , Carboplatin Treating Patients With Unresectable Stage IIIB Stage IV Non-Small Cell Lung Cancer High Risk Hemoptysis Caused Bevacizumab</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Evaluate safety prophylactic chest radiotherapy , bevacizumab , paclitaxel , carboplatin patient unresectable stage IIIB IV non-small cell lung cancer high risk bevacizumab-associated hemoptysis . SECONDARY OBJECTIVES : I. Assess progression-free survival patient treat regimen . II . Assess rate objective response , overall survival , time response , response duration irradiate lesion non-irradiated lesion patient . OUTLINE : This open-label , pilot , multicenter study . Patients assign sequentially 1 2 treatment stratum . Stratum I : Patients undergo prophylactic radiotherapy day 1-5 8-12 . Patients receive paclitaxel IV 3 hour carboplatin IV 30-60 minute day 15 . Patients also receive paclitaxel IV 3 hour carboplatin IV 30-60 minute bevacizumab IV 30-90 minute day 36 ( course 2 ) . Stratum II : Patients undergo prophylactic radiotherapy receive paclitaxel carboplatin stratum I . Patients also receive bevacizumab IV 30-90 minute day 15 ( course 1 ) . In stratum , treatment paclitaxel , carboplatin , bevacizumab repeat every 21 day 5-6 course absence disease progression unacceptable toxicity . Patients complete partial response stable disease may continue receive single-agent bevacizumab every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 12 month . PROJECTED ACCRUAL : A total 72 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Hemoptysis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically confirm primary nonsmall cell lung cancer ( NSCLC ) * meet follow criterion : Squamous cell mixed squamousnonsquamous histology predominant squamous component ( ≥ 50 % squamous ) primary , unresected endobronchial lesion No small cell component Centrally locate primary tumor , define follow : Primary tumor T stage within touch zone proximal bronchial tree Zone define 3dimensional volume perimeter 2 cm direction around proximal bronchial tree ( carina , right leave main bronchus , right leave upper lobe bronchus , intermedius bronchus , right middle lobe bronchus , lingular bronchus , right leave low lobe bronchus ) Any disease within volume must invade blood vessel determine contrastenhanced CT scan evaluation entire thorax thin slice ( ≤ 5 mm ) area central tumor bulk ( i.e. , evidence vessel invasion radiological evaluation ) Stage IIIB ( malignant pleural effusion ) stage IV disease Patients stage IIIB NSCLC without effusion eligible candidate combine modality therapy curative intent ( i.e. , radical chemoradiotherapy ) At high risk bevacizumabassociated hemoptysis Hemoptysis estimate 2.5 mL 10 mL ( large volume single episode hemoptysis ) past 2 month Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan No known brain metastasis contrastenhanced CT scan gadoliniumenhanced MRI brain No clinical radiologic evidence exist impend spinal cord compression ECOG performance status ( PS ) 01 OR Karnofsky PS 70100 % Life expectancy &gt; 6 month WBC ≥ 3,000/mm³ Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Bilirubin normal AST ALT ≤ 2.5 time upper limit normal ( ULN ) Creatinine normal OR creatinine clearance ≥ 50 mL/min INR &lt; 1.5 aPTT ≤ 1.5 time ULN No serious medical condition , include follow : Unstable angina Myocardial infarction stroke ( cerebrovascular accident transient ischemic attack ) within past 6 month Congestive heart failure Active cardiomyopathy Unstable ventricular arrhythmia Symptomatic peripheral vascular disease Active peptic ulcer disease Uncontrolled psychotic disorder Serious infection Other medical condition potentially aggravate treatment No social situation would preclude study compliance No active malignancy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 6 month completion study treatment No history bleed diathesis coagulopathy associate elevate risk bleed No uncontrolled hypertension ( i.e. , rest blood pressure consistently high systolic &gt; 150 mm Hg and/or diastolic &gt; 100 mm Hg without antihypertensive medication ) , history labile hypertension , history poor compliance antihypertensive medication No clinically significant proteinuria ( 24hour urine protein &lt; 1,000 mg ) No serious nonhealing wound , ulcer , bone fracture No abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 28 day No significant traumatic injury within past 28 day No history know allergy reaction attribute compound similar chemical biological composition bevacizumab , Chinese hamster ovary cell protein recombinant human humanize antibody , Cremophor EL® , agent use study treatment No preexist peripheral neuropathy &gt; grade 1 No prior thoracic radiotherapy At least 12 month since prior chemotherapy No prior chemotherapy advanced disease No prior therapy angiogenesis , vascular endothelial growth factor ( VEGF ) , VEGFreceptor inhibitor Cyclooxygenase2 inhibitor noncancer therapy allow At least 28 day since prior concurrent major surgery open biopsy At least 12 month since prior anticancer therapy malignancy except basal cell carcinoma skin , localized prostate cancer , situ carcinoma cervix At least 10 day since prior therapeutic anticoagulant therapeutic thrombolytic agent No concurrent aspirin ( &gt; 325 mg/day ) antiplatelet agent , include dipyridamole , ticlopidine , clopidogrel bisulfate , cilostazol Other concurrent nonsteroidal antiinflammatory drug allow No concurrent investigational agent No concurrent combination antiretroviral therapy HIVpositive patient No concurrent anticancer agent therapy Steroids pain , anorexia , quality life allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>